Who owns Corvus Pharmaceuticals?
- Ticker: CRVS
- CUSIP Number: 221015100
Tip: Access positions for across all investors
Analyze quarterly positions in Corvus Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv

Top investors of Corvus Pharmaceuticals stock
Who bought or sold Corvus Pharmaceuticals this quarter?
Fund or Company Name |
Shares Held |
Valued At |
Change in Shares |
As Of |
Actions |
---|---|---|---|---|---|
OrbiMed Advisors | 6.9M | $37M | 0% | Dec 2024 |
|
Samlyn Capital | 6.7M | $36M | 47% | Dec 2024 |
|
Adams Street Partners | 3.3M | $18M | 0% | Dec 2024 |
|
Point72 Asset Management | 3.0M | $16M | -46% | Dec 2024 |
|
Rtw Investments | 2.7M | $14M | 100% | Dec 2024 |
|
Vanguard Group | 2.5M | $13M | 1% | Dec 2024 |
|
Vivo Capital | 2.2M | $12M | 49% | Dec 2024 |
|
Susquehanna International | 1.3M | $6.9M | 331% | Dec 2024 |
|
Ikarian Capital | 1.3M | $6.7M | 475% | Dec 2024 |
|
Goldman Sachs Group | 1.1M | $5.8M | 24% | Dec 2024 |
|
BlackRock | 1.1M | $5.7M | 78% | Dec 2024 |
|
Deerfield Management Company | 1.0M | $5.4M | 100% | Dec 2024 |
|
Caption Management | 631k | $3.4M | 100% | Dec 2024 |
|
Geode Capital Management | 567k | $3.0M | 1% | Dec 2024 |
|
Sphera Funds Management | 501k | $2.7M | 100% | Dec 2024 |
|
Qube Research & Technologies | 450k | $2.4M | 253% | Dec 2024 |
|
Morgan Stanley | 397k | $2.1M | 1% | Dec 2024 |
|
Renaissance Technologies | 391k | $2.1M | 1% | Dec 2024 |
|
Citadel Advisors | 377k | $2.0M | 107% | Dec 2024 |
|
Boothbay Fund Management | 363k | $1.9M | 469% | Dec 2024 |
|
Jane Street | 347k | $1.9M | 590% | Dec 2024 |
|
Millennium Management | 336k | $1.8M | -28% | Dec 2024 |
|
State Street Corporation | 206k | $1.1M | 15% | Dec 2024 |
|
LMR Partners | 153k | $816k | 100% | Dec 2024 |
|
Simplex Trading | 140k | $748k | 2368% | Dec 2024 |
|
Schonfeld Strategic Advisors | 129k | $691k | -61% | Dec 2024 |
|
EntryPoint Capital | 117k | $624k | 100% | Dec 2024 |
|
Raymond James Financial | 109k | $583k | 100% | Dec 2024 |
|
Barclays | 106k | $567k | 10601800% | Dec 2024 |
|
Northern Trust | 106k | $567k | 1% | Dec 2024 |
|
Squarepoint Ops | 98k | $525k | 712% | Dec 2024 |
|
Bank of America Corporation | 97k | $519k | 23612% | Dec 2024 |
|
Engineers Gate Manager | 85k | $453k | 100% | Dec 2024 |
|
TowerView | 78k | $415k | -34% | Dec 2024 |
|
OMERS Administration Corporation | 76k | $404k | 100% | Dec 2024 |
|
Longwood Capital Partners | 74k | $398k | 100% | Dec 2024 |
|
Jackson Square Capital | 64k | $203k | 0% | Mar 2025 |
|
XTX Topco | 57k | $306k | 306% | Dec 2024 |
|
Group One Trading | 53k | $282k | 849% | Dec 2024 |
|
UBS Group | 52k | $279k | 232% | Dec 2024 |
|
Hikari Power | 50k | $267k | 0% | Dec 2024 |
|
Balyasny Asset Management | 48k | $259k | 100% | Dec 2024 |
|
Citigroup | 48k | $258k | -61% | Dec 2024 |
|
American Century Companies | 44k | $234k | 140% | Dec 2024 |
|
Bridgeway Capital Management | 41k | $221k | -68% | Dec 2024 |
|
UBS O'Connor | 40k | $214k | 100% | Dec 2024 |
|
Ancora Advisors | 38k | $203k | 63% | Dec 2024 |
|
GSA Capital Partners | 36k | $193k | 100% | Dec 2024 |
|
Gillespie Robinson & Grimm | 33k | $104k | 10% | Mar 2025 |
|
Two Sigma Investments | 30k | $162k | -58% | Dec 2024 |
|
Masso Torrence Wealth Management | 30k | $161k | 100% | Dec 2024 |
|
Charles Schwab Investment Management | 30k | $160k | 91% | Dec 2024 |
|
ADAR1 Capital Management | 25k | $134k | 100% | Dec 2024 |
|
Jpmorgan Chase & Co | 25k | $131k | -51% | Dec 2024 |
|
Dimensional Fund Advisors | 23k | $122k | 91% | Dec 2024 |
|
Three Bridge Wealth Advisors | 22k | $120k | 100% | Dec 2024 |
|
Quinn Opportunity Partners | 22k | $119k | 0% | Dec 2024 |
|
Commerce Bank N A | 20k | $107k | 0% | Dec 2024 |
|
Graham Capital Management | 18k | $98k | 100% | Dec 2024 |
|
Oppenheimer & Co | 18k | $97k | 6% | Dec 2024 |
|
Two Sigma Advisers | 18k | $96k | -71% | Dec 2024 |
|
Advisor Group Holdings | 17k | $88k | 0% | Dec 2024 |
|
Jain Global | 17k | $89k | 100% | Dec 2024 |
|
Hrt Financial | 16k | $87k | 100% | Dec 2024 |
|
Virtu Financial | 16k | $86k | 2% | Dec 2024 |
|
Nwam | 16k | $83k | 54% | Dec 2024 |
|
Tower Research Capital | 14k | $74k | 100% | Dec 2024 |
|
China Universal Asset Management | 14k | $73k | 100% | Dec 2024 |
|
Man Group | 14k | $73k | 100% | Dec 2024 |
|
ExodusPoint Capital Management | 14k | $72k | 100% | Dec 2024 |
|
Sowell Financial Services | 12k | $38k | 100% | Mar 2025 |
|
Alpine Partners VI | 12k | $62k | 100% | Dec 2024 |
|
Whittier Trust Co. of Nevada | 11k | $60k | 0% | Dec 2024 |
|
Virtus ETF Advisers | 8.8k | $47k | 100% | Dec 2024 |
|
Rothschild Investment | 7.0k | $22k | 0% | Mar 2025 |
|
Royal Bank of Canada | 5.0k | $27k | 100% | Dec 2024 |
|
Northwest Capital Management | 3.4k | $18k | 0% | Dec 2024 |
|
Mirae Asset Global Investments | 2.1k | $11k | 100% | Dec 2024 |
|
Western Pacific Wealth Management | 2.0k | $6.4k | 0% | Mar 2025 |
|
Gf Fund Management | 1.3k | $7.2k | 100% | Dec 2024 |
|
SBI Securities | 1.0k | $5.4k | 100% | Dec 2024 |
|
Bnp Paribas Arbitrage, Snc | 861.00 | $4.6k | -72% | Dec 2024 |
|
Rhumbline Advisers | 791.00 | $2.5k | 0% | Mar 2025 |
|
Signature | 224.00 | $1.2k | 100% | Dec 2024 |
|
Wells Fargo & Company | 169.00 | $903.997900 | 100% | Dec 2024 |
|
EverSource Wealth Advisors | 60.00 | $321.000000 | 100% | Dec 2024 |
|
FMR | 5.00 | $29.000000 | -50% | Dec 2024 |
|
Who sold out of Corvus Pharmaceuticals?
Fund or Company Name |
Date Sold |
Shares Held |
Valued At |
---|---|---|---|
Marshall Wace | Sep 2024 | 323k | $1.7M |
Connor, Clark & Lunn Investment Management | Sep 2024 | 137k | $724k |
Acadian Asset Management | Sep 2024 | 80k | $420k |
Wolverine Trading | Sep 2024 | 42k | $214k |
Mission Wealth Management | Sep 2024 | 40k | $211k |
Cubist Systematic Strategies | Sep 2024 | 10k | $53k |
Resources Investment Advisors | Sep 2024 | 10k | $53k |
IFP Advisors | Sep 2024 | 24.00 | $127.000800 |